Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ketamine may help patients with depression - study
The study was conducted by scientists at Janssen Research and Development in New Jersey.

Medication might become available on the NHS

The anaesthetic drug ketamine may help to decrease suicidal feelings and depression, according to new research.

The study published in the American Journal of Psychology tested the effect of ketamine on patients rated at risk and in need of hospitalisation. It found that ketamine administered via a nasal spray, together with anti-depressant treatment, cut suicidal thoughts and depression in around four hours.

Researchers say the nasal spray did not exceed that of a placebo with antidepressent treatment at the end of the four-week trial. However, the effects of the spray were profound and similar to those achieved with intravenous ketamine. The spray is now going through phase three trials before it is approved for marketing.

Whilst the study does not report any misuse of ketamine, its authors warn that further research is required on the probable mistreatment of the drug. In recent years, ketamine has been used recreationally, prompting moves to control the substance under international law.

Dr James Stone from the Royal College of Psychiatrists told BBC News the study confirmed the findings from studies into intravenous ketamine that had been successful.

"The main reason for its significance is because this is being developed by a drug company and it's potentially quite likely that this medication might become available as a treatment available on the NHS for depression,” he said.

Dr Stone added that because the ketamine was being administered as a nasal spray, it was “much easier to administer than intravenous ketamine” and “potentially quicker to give”. 

He said that if the drug was to go on to be prescribed on the NHS, it would be aimed at those with severe depression if other drugs had failed.

The study was conducted by scientists at Janssen Research and Development in New Jersey, a Johnson & Johnson company, and the Yale School of Medicine. 

Become a member or log in to add this story to your CPD history

New app to improve street dog welfare

News Story 1
 A new free app will support vital work in clinics caring for stray dogs around the world, experts say. Created by the University of Edinburgh, the tool allows vets to track the wellbeing of dogs going through catch-neuter-return schemes, which are common in countries with large numbers of strays.

Vets say the welfare of individual dogs can be overlooked during the process of capture, transport or surgery. The app, piloted across Asia and Africa, helps staff to monitor welfare, spot signs of distress and develop strategies to improve care. It was launched at BSAVA Congress on Friday 6 April.  

Click here for more...
News Shorts
Farm to fork traceability championed in new service

Defra has created a new information service to offer farm to fork traceability when the UK leaves the EU. The Livestock Information Service, which is set to be operational from 2019, will identify and track animal movements via electronic IDs, meaning the industry and government are better placed to respond in the event of a disease outbreak.

Environment secretary Michael Gove said: “This service will be instrumental in improving traceability and providing guarantees to consumers about the origin of their food. NFU President Minette Batters, among others, has helped lead the way on this, showing how it will drive a progressive and vibrant livestock industry once we leave the EU.”